



## Health

Public Health  
4<sup>th</sup> Floor; 300 Carlton Street Winnipeg MB R3B 3M9  
[vaccines@gov.mb.ca](mailto:vaccines@gov.mb.ca)

April 3, 2023

Dear Health Care Provider:

### **Moderna Product Updates**

1. **Moderna (Spikevax™) Monovalent (6+) vaccine supply**
  - The current supply of Moderna monovalent vaccine expires on April 23, 2023.
  - No more monovalent vaccine supply is anticipated from Moderna at this time. This has been removed from the weekly ordering surveys.
  - If partners have supply and the product has not expired, it can continue to be administered.
  - Going forward, Pfizer monovalent is available as an option.
2. **Transition to Moderna (Spikevax™) Bivalent BA.4/5 vaccine**
  - The current supply of Moderna bivalent **BA.1** vaccine expires on April 10, 2023.
  - The **BA.4/5** bivalent vaccine will begin distribution in Manitoba the week of April 3, 2023.
  - A new tariff code has been added to PHIMS for the BA.4/5 bivalent vaccine (#8227). An updated tariff cost listing can be located at:  
<https://www.gov.mb.ca/covid19/health-care-providers.html>.
  - Remaining BA.1 bivalent vaccine should be removed from the fridge and not used either 30 days after receiving it from the provincial vaccine warehouse or on the expiry date, whichever comes sooner.
3. **Moderna (Spikevax™) Infant vaccine availability**
  - Moderna Infant will be included in the weekly order surveys on March 31, 2023.
  - Product is anticipated to arrive in Manitoba the week of April 3, 2023 and will be distributed to providers the week of April 10, 2023.
  - All infants 6 months to 4 years of age will be eligible for a 2-dose series (3-dose series required for those immunocompromised) when the product is available.
  - Pfizer infant continues to be available as well.

The Storage and Handling Quick Reference Guide is located at:  
[https://www.gov.mb.ca/asset\\_library/en/covidvaccine/storage-handling-chart.pdf](https://www.gov.mb.ca/asset_library/en/covidvaccine/storage-handling-chart.pdf).

Please share this information with colleagues at your clinic/facility.

Sincerely,



Richard Baydack, PhD  
Director  
Communicable Disease Control



Davinder Singh, MD, MSc, FRCPC  
Medical Lead, Vaccines,  
Communicable Disease Control